A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
Authors
Keywords
-
Journal
Journal of Immunology Research
Volume 2017, Issue -, Pages 1-9
Publisher
Hindawi Limited
Online
2017-12-11
DOI
10.1155/2017/6940546
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical applications of PD-L1 bioassays for cancer immunotherapy
- (2017) Delong Liu et al. Journal of Hematology & Oncology
- PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
- (2017) Jun Wang et al. Journal of Hematology & Oncology
- Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
- (2017) Jesus García-Donas et al. LANCET ONCOLOGY
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy
- (2017) Yang‐Min Ning et al. ONCOLOGIST
- Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas
- (2017) Jeanny B. Aragon-Ching UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Expanding Immunotherapy Options for Bladder Cancer
- (2017) Jean-Michel Lavoie et al. UROLOGY
- Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
- (2017) Hampig Raphael Kourie et al. OncoTargets and Therapy
- Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
- (2017) Clizia Zichi et al. Biomed Research International
- Bladder cancer
- (2017) Oner Sanli et al. Nature Reviews Disease Primers
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
- (2017) Shilpa Gupta et al. Cancers
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
- (2016) A. Balar et al. ANNALS OF ONCOLOGY
- Cancer immunotherapy
- (2016) Stephanie A. Mullane et al. CURRENT OPINION IN UROLOGY
- Atezolizumab: First Global Approval
- (2016) Anthony Markham DRUGS
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma
- (2016) Moshe C. Ornstein et al. Expert Review of Anticancer Therapy
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
- (2016) Shuhang Wang et al. Journal of Hematology & Oncology
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Anti-PD-L1 inhibitor durvalumab in bladder cancer
- (2016) Vicki Brower LANCET ONCOLOGY
- Making urothelial carcinomas less immune to immunotherapy
- (2016) Jorge D. Ramos et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Emerging role of immunotherapy in urothelial carcinoma—Future directions and novel therapies
- (2016) Jong Chul Park et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia
- (2015) Masatomo Miura BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Future Directions and Targeted Therapies in Bladder Cancer
- (2015) Guru Sonpavde et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
- (2015) M. Callea et al. Cancer Immunology Research
- Melanoma immunotherapy
- (2014) Martina Sanlorenzo et al. CANCER BIOLOGY & THERAPY
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer
- (2013) C. Chung et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent Advances in Treatment of Advanced Urothelial Carcinoma
- (2012) Jenny J. Kim Current Urology Reports
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now